What did @risinghealthreport actually say?
The creator walked through drawing compounded tirzepatide from a vial using a small insulin syringe, noting it differs physically from brand-name Zepbound, which uses an auto-injector pen. They described wiping the vial with alcohol, drawing more than needed, waiting for bubbles to rise, then pushing back to the target volume. Their stated dose was "32 units" on the syringe, described as corresponding to a 2.5 mg dose.
They also mentioned injecting subcutaneously and massaging the site afterward. The tone was casual and instructional, framed as personal experience rather than medical guidance. For nearly 300,000 viewers, this is functioning as a how-to guide for self-administered injectable medication, which carries real stakes.
Does the science back this up?
The mechanical steps described, drawing from a vial, clearing bubbles, and injecting subcutaneously, are broadly consistent with standard subcutaneous injection technique. But the unit-to-milligram conversion claim deserves scrutiny, because it is concentration-dependent and the creator never states the concentration of their compounded vial.
Tirzepatide's FDA-approved formulations (Mounjaro, Zepbound) are fixed-concentration prefilled devices. Compounded tirzepatide vials vary in concentration depending on the compounding pharmacy. A common compounded concentration is 5 mg/mL, in which case 2.5 mg would equal 0.5 mL, or 50 units on a standard U-100 insulin syringe. The creator says 2.5 mg equals 32 units, which implies a concentration of roughly 7.8 mg/mL. That is not impossible, but it is not a standard concentration, and no label is readable in the video. The FDA's 2024 guidance on compounded tirzepatide specifically warned that variable concentrations create dosing confusion and error risk (FDA Drug Safety Communication, 2024).
What did they get right and wrong?
Credit where it is due: wiping the vial septum with an alcohol swab before drawing is correct practice. Using a fine-gauge insulin needle for subcutaneous GLP-1 injections is appropriate. Drawing slightly more than needed and then dialing back to remove air bubbles is a legitimate technique taught in clinical settings.
What they got wrong, or at minimum glossed over, is significant. First, the unit conversion math is presented with confidence but is only valid if you know the vial's concentration, which was never disclosed. Second, the phrase "push air in before it doesn't really matter" is wrong. Injecting air into a multi-dose vial is a standard technique used to equalize pressure for easier drawing, but the creator's explanation, that it doesn't matter because the dose is small, misrepresents why it's done. Third, site massage after a subcutaneous GLP-1 injection is generally not recommended in clinical protocols, as it can alter absorption and increase local irritation. Studies on subcutaneous insulin and GLP-1 analogue absorption suggest consistent, undisturbed injection sites improve pharmacokinetic reliability (Frid et al., 2016, Diabetes Technology and Therapeutics).
What should you actually know?
If you are using compounded tirzepatide, the single most important thing on your vial is the concentration, expressed as mg/mL. Without it, unit counts on a syringe are meaningless numbers. Do not assume your vial matches anyone else's, including a TikTok creator's.
Compounded tirzepatide is not the same product as FDA-approved Mounjaro or Zepbound. It may contain tirzepatide base rather than the salt form used in approved products, and the FDA has raised concerns about potency and sterility variability in compounded versions (FDA Statement on Compounded Tirzepatide, June 2024). That does not mean compounded versions are universally unsafe, but it does mean the risk profile is different and the dosing math cannot be borrowed from someone else's video.
Site rotation, not massage, is the evidence-backed approach for subcutaneous injectables. Abdomen, thigh, and upper arm are standard sites. Always consult the prescribing clinician about your specific vial's concentration before drawing anything.
The bottom line
This video is well-intentioned and gets some basics right, but it presents concentration-dependent dosing information as universal, which it is not. The injection technique is mostly reasonable, the unit math is not verifiable without knowing the vial's concentration, and site massage is not standard practice. For a medication with a narrow therapeutic window and real GI side effect risks, the difference between 2.5 mg and an unintended higher dose matters.